TrialRMD open2021

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.

Christopher T Ritchlin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.